NAD+ Precursor Showdown: What the 2026 Clinical Data Actually Shows on NMN vs NR.
Both nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) reliably raise blood NAD+ levels. The supplement industry treats that fact as the end of the conversation. The 2026 head-to-head human data shows it is the beginning — because blood NAD+ and tissue NAD+ are not the same thing, and the downstream signals these two molecules pull are not identical.
What NAD+ is, and why it declines
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell in the body. It sits at the center of energy metabolism, shuttling electrons through the mitochondrial electron transport chain to produce ATP (adenosine triphosphate) — the cellular energy currency. That is the textbook role. The reason it matters for aging is a different function entirely: NAD+ is the essential substrate for sirtuins (SIRTs) and poly-ADP-ribose polymerases (PARPs), two enzyme families that regulate DNA repair, gene expression, and mitochondrial biogenesis. When NAD+ levels drop, that signaling capacity drops with it.
They drop considerably with age. Human tissue studies show whole-blood and skeletal muscle NAD+ declining by roughly 50% between the third and seventh decades of life [6]. The mechanism behind this decline is not a single lever — it is two levers pulling in opposite directions.
The first is CD38 (cluster of differentiation 38), an enzyme that consumes NAD+ as part of its signaling function. CD38 expression increases with age and with inflammation in both mouse models and, to a more limited extent, in human adipose tissue samples. More CD38 means faster NAD+ degradation, and mouse knockout data identifies it as a primary driver of the age-related decline; direct human causal evidence is still accumulating [7]. The second lever is NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway — the main route by which cells recycle nicotinamide back into NAD+. NAMPT activity declines with age, slowing the cell's ability to regenerate its own NAD+ pool [6].
The result is a double problem: the drain accelerates while the refill mechanism weakens. This is the biological premise behind supplementing NAD+ precursors — feeding the salvage and biosynthesis pathways upstream of the bottleneck. The question is which precursor feeds which pathway, how efficiently, and in which tissues. Those are not marketing questions. They are now, finally, clinical ones.
Oral NAD+ is not bioavailable. The molecule is too large and charged to cross cell membranes intact, and it is degraded to smaller metabolites in the gut before meaningful absorption can occur. The entire NAD+ precursor category exists because you have to feed the synthesis pathway upstream — you cannot top up the tank directly. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two precursors that have reached human clinical trials at meaningful scale.
Two routes into the NAD+ pool — NMN and NR
NMN and NR are structurally related — NMN is essentially NR with a phosphate group added — but their uptake mechanisms differ in ways that shape where each molecule ends up in the body.
Nicotinamide riboside (NR) enters cells primarily through equilibrative nucleoside transporters (ENTs), which are broadly expressed across most tissue types. Once inside, NR is phosphorylated by nicotinamide riboside kinases (NRKs) into NMN, then into NAD+. The ENT pathway is well characterized and the oral bioavailability of NR is confirmed in multiple human studies [4]. The conversion step from NR to NMN happens intracellularly, meaning the phosphorylation enzyme becomes the rate-limiting factor for tissue uptake under high supplementation loads.
Nicotinamide mononucleotide (NMN) has a more contested uptake story. Early models assumed NMN was dephosphorylated in the gut to NR before absorption — essentially making it a slow-release NR precursor. More recent evidence identified a specific transporter, Slc12a8, that appears to transport NMN directly across intestinal cells without dephosphorylation in some tissues [11]. (Note: Slc12a8 is a member of the SLC12 cation-chloride cotransporter family; the "SmCT2" label sometimes used in community discussion refers to an unrelated sodium-coupled monocarboxylate transporter and is a nomenclature error.) This identification remains contested — a 2019 rebuttal in the same journal challenged the analytical methods underlying the Slc12a8 assignment, and the transporter's functional significance in humans is not yet settled. If that pathway does operate significantly in humans, NMN enters the NAD+ pool via a distinct route from NR. The clinical implication: the two molecules are not interchangeable inputs just because they share the same endpoint.
The gut is also worth examining as a site of action in its own right, not just a transit point. The intestinal wall has high NAD+ turnover and expresses both NRK enzymes and the Slc12a8 transporter. This means a meaningful fraction of orally consumed NMN may be converted to NAD+ locally in gut epithelial cells — before reaching systemic circulation — which has implications for gut microbiome interactions that have emerged in the 2026 data.
Blood NAD+ rising is not the signal. Blood NAD+ rising is the measurement we have. The signal is what happens in the tissue — and that is a different question.
Head-to-head: what the 2026 human data shows
For the first several years of the NAD+ precursor era, clinical data on NMN and NR existed in separate silos. NR was first to human trials, with foundational bioavailability data published in 2016 confirming oral NR raises blood NAD+ metabolites dose-dependently in healthy adults [4]. NMN trials followed, with the Yoshino group's landmark 2021 study demonstrating that ten weeks of 250 mg daily NMN significantly improved muscle insulin sensitivity in postmenopausal prediabetic women — the first clean human signal for a functional downstream benefit beyond biomarker uplift [1].
The Elhassan group's 2019 NR trial in older men (n=12, median age 75, 1 g/day for 21 days) showed NR shifted the skeletal muscle NAD+ metabolome — NAAD and nicotinamide clearance products rose significantly — and induced anti-inflammatory gene expression changes [2]. Critically, skeletal muscle NAD+ itself did not increase significantly (p=0.22), suggesting the cohort may have had pre-existing NAD+ sufficiency. The metabolome shift is real; the functional uplift in this small, short trial is less certain than the headline framing suggests.
What the 2026 picture adds — through accumulating head-to-head metabolomics data and comparison analyses across trials — is a clearer differentiation of downstream effects. The findings, taken together, point in three directions:
Blood NAD+ uplift: roughly equivalent. Both NMN and NR raise whole-blood NAD+ and total NAD+ metabolite levels at comparable doses. The magnitude of uplift is dose-dependent for both. Neither molecule has demonstrated definitively superior blood bioavailability in head-to-head human dosing. For the supplement industry, this is where the comparison ends. It should not be.
Gut microbiome modulation: NMN shows a stronger signal — in animal models. The intestinal exposure of NMN — and its direct conversion in gut epithelial cells — appears to produce distinct effects on the microbiome that NR does not replicate. In mouse studies, NMN supplementation has been associated with shifts in short-chain fatty acid (SCFA) producing bacterial populations, including increases in butyrate-producing species (Ruminococcaceae, Akkermansia muciniphila) and corresponding changes in SCFA output. The clinical relevance of these microbiome shifts for systemic inflammation and metabolic health is plausible; butyrate is a potent histone deacetylase (HDAC) inhibitor and gut barrier support molecule. This effect appears linked to the direct gut wall action of NMN and is not simply a consequence of raising NAD+ systemically. Whether this translates to meaningful human microbiome changes has not been established in powered clinical trials. NR's ENT-mediated uptake does not appear to produce the same magnitude of local intestinal effect in the available preclinical data.
Brain bioavailability: early evidence favors NR in some pathways. The ENT transporters through which NR is absorbed are expressed in the blood-brain barrier. Some mechanistic and animal-model data suggests NR crosses into the central nervous system more efficiently than NMN, which — absent robust Slc12a8 expression in the blood-brain barrier — may be partially converted to NR in circulation before crossing. This is a provisional signal. Direct human brain NAD+ measurement via 31P magnetic resonance spectroscopy is an active research area but not yet at scale. The brain bioavailability question is the most important open question in the field for neurological aging applications, and the answer as of 2026 is: genuinely unsettled, with NR holding a plausible mechanistic edge that has not yet been confirmed in powered human trials.
Irie and colleagues randomized 10 healthy Japanese men to 12 weeks of 250 mg daily NMN versus placebo in a crossover design. Blood NAD+ metabolites rose significantly. Fasting blood glucose, triglycerides, and inflammatory markers did not change significantly in this population. Crucially, no adverse events were reported [9]. The trial is small and short. It establishes safety and biomarker uplift at a common community-use dose. It does not establish functional or longevity benefit.
The Mills 2016 mouse study remains the most complete mechanistic demonstration of long-term NMN administration reversing age-associated physiological decline — including improved energy metabolism, insulin sensitivity, eye function, bone density, and immune function — but this was in mice, with lifespan as an interpretable endpoint [8]. The translation to humans for hard longevity endpoints has not been demonstrated. The Remie 2020 NR study in healthy obese humans showed skeletal muscle acetylcarnitine shifts and modest body composition changes over six weeks of 1000 mg daily NR — a signal for metabolic activity, not longevity [10].
The Mehmel 2020 comprehensive NR review across available human and animal data concluded that while NR consistently raises blood NAD+ and shows promise in metabolic disease contexts, the evidence for cognitive, cardiovascular, or lifespan benefit in humans remains insufficient to make definitive claims [5]. That assessment has not materially changed with 2025–2026 additions to the literature. What has changed is the resolution of the mechanistic picture, which now supports treating NMN and NR as distinct interventions rather than interchangeable ones.
Blood NAD+ vs tissue NAD+ — the distinction that matters
This is the section the supplement labels skip. Whole-blood NAD+ measurement is accessible, reproducible, and commercially available. Tissue NAD+ measurement — in muscle, liver, brain, or kidney — requires biopsy or specialized imaging and is done in research settings only. The gap between these two measurements is not trivial.
The Elhassan 2019 trial used muscle biopsy to confirm that NR supplementation raised skeletal muscle NAD+ — not just blood NAD+ — in older adults [2]. This is meaningful because skeletal muscle is a major metabolic sink and is one of the tissues where NAMPT decline is well documented. But even this confirmation came with a caveat: the NAD+ metabolome shift in muscle included increases in NAAD (nicotinic acid adenine dinucleotide), which suggests the NR is being routed through pathways that don't all converge on the sirtuin-activating NAD+ pool in the expected way.
The Yoshino 2021 NMN study used a different endpoint: muscle insulin sensitivity via hyperinsulinemic-euglycemic clamp — a gold-standard metabolic measure, not a biomarker proxy [1]. That design choice matters. It measured a functional outcome in muscle, which is more meaningful than measuring blood NAD+ and assuming the tissue effect follows. The finding — improved muscle insulin sensitivity with NMN — is the strongest functional human signal in the precursor literature to date. It is also specific to prediabetic postmenopausal women. Generalization requires more populations.
The honest version of the tissue story: blood NAD+ is the best available proxy we have for most individuals considering supplementation. It is not a direct measure of what is happening in the tissues where aging matters most — brain, heart muscle, skeletal muscle, and liver. Every time a supplement company shows you a blood NAD+ graph, you are looking at a proxy, not the endpoint. The proxy is meaningful. It is not the signal itself.
For brain NAD+ specifically, the absence of accessible measurement tools is the main reason the cognitive aging application of NAD+ precursors remains speculative. Animal models show brain NAD+ declining with age and NMN or NR administration restoring it. Human brain NAD+ imaging data is sparse. The clinical trials on cognitive outcomes in humans using NAD+ precursors have been small and have not shown consistent results. This is not evidence that brain NAD+ supplementation doesn't work — it is evidence that we don't have the tools or the adequately powered trials yet.
No human trial of NMN or NR has demonstrated lifespan extension, reduction in all-cause mortality, or meaningful delay of clinical disease onset. The animal data — particularly the NMN mouse work from the Mills group and earlier ITP-adjacent studies — is genuinely compelling. Translation to human longevity outcomes has not been demonstrated. Biomarker uplift is not a longevity benefit. It is a hypothesis-generating signal.
Dosing, timing, and who benefits most
The functional dosing range in human trials is 250–1000 mg daily for both NMN and NR. The Yoshino insulin sensitivity signal emerged at 250 mg daily NMN. The Elhassan muscle NAD+ data used 1000 mg daily NR. The Remie body composition data used 1000 mg daily NR. Neither molecule has a dose-finding trial in healthy adults large enough to establish a clean dose-response curve for functional outcomes — the dose-response literature is stronger for blood NAD+ uplift than for anything downstream.
Timing with exercise has mechanistic logic behind it. Exercise induces NAMPT expression and upregulates the NAD+ salvage pathway acutely. Taking NMN or NR in proximity to a training session may amplify the signal by flooding a pathway that the exercise stimulus has already primed. This is a plausible hypothesis with some mechanistic support and limited direct human trial validation. Community use has settled on pre-workout or morning dosing for this reason. The data does not yet confirm optimal timing in humans.
Who benefits most: the clearest functional signals have emerged in populations where NAD+ decline is most pronounced — older adults (over 55), individuals with metabolic dysfunction or prediabetes, and those with documented exercise intolerance or skeletal muscle weakness. Healthy adults under 40 with intact NAMPT function and no metabolic disease have the least established rationale for supplementation and are the population for whom the cost-benefit calculation is most uncertain. The "everyone over 30 should be on NAD+ precursors" claim in circulation is not supported by the trial evidence.
NMN vs NR choice in practice: if the primary target is metabolic health and gut microbiome modulation, the current evidence tilts toward NMN — the Yoshino insulin sensitivity data and the emerging microbiome differentiation data both favor it for metabolic applications. If the primary concern is potential neurological protection, the mechanistic case for NR's ENT-mediated brain bioavailability is worth weighing, pending human confirmation. Neither answer is definitive. Both molecules have a real evidence base; neither has a complete one.
Safety profile: both NMN and NR have clean safety records across the published human trials. The Irie NMN trial, Yoshino NMN trial, Elhassan NR trial, and Remie NR trial all report no significant adverse events at the doses studied. Nausea at higher doses (above 1000 mg) has been noted anecdotally. The six-week to twelve-week trial durations in most studies do not capture long-term safety data for chronic use over years — that data does not yet exist at the scale needed to be conclusive. If you are considering supplementation, speak with a clinician before starting, particularly if you have metabolic disease, are on medication, or have a personal or family history of cancer.
A tiered framework
We do not write protocols. We write frameworks that you take to a clinician — or use to calibrate your own informed decision about supplementation. With that established:
Exercise is the single most potent NAMPT inducer available without a prescription. Resistance training and aerobic exercise both upregulate the NAD+ salvage pathway. If your training is inconsistent, sleep is poor, and diet is metabolically disorganized, no NAD+ precursor dose will outrun those deficits. The conservative position: build the foundation before adding precursors. The supplement amplifies a signal that needs to be there first.
Adults over 45 with intact metabolic health who want to address age-related NAD+ decline have a reasonable evidence base to work from. NMN at 250–500 mg daily has the strongest functional human data (Yoshino 2021). NR at comparable doses has the strongest skeletal muscle bioavailability confirmation (Elhassan 2019). Baseline whole-blood NAD+ testing before and after 8–12 weeks establishes whether you are a responder. Not everyone is.
Higher doses with structured resistance training and aerobic conditioning, under clinician monitoring for metabolic markers (fasting glucose, HbA1c, lipids), represent the protocol space where the NMN functional data is most relevant. CD38 expression increases with obesity and chronic inflammation — addressing those upstream before or alongside precursor supplementation changes the math on NAD+ degradation rate. At this tier, the combination of reduced CD38 activation and precursor supplementation has stronger theoretical backing than precursor supplementation alone.
Supplementing NAD+ precursors without addressing CD38 overactivity is like adding water to a bucket with a drain. CD38 expression is driven by inflammation — specifically by senescent cell accumulation and NF-κB signaling. Quercetin and apigenin have some evidence as CD38 inhibitors in animal models; the human data is thin. But the concept is correct: the NAD+ floor you can raise is limited by how fast the drain is running. Chronic inflammation is the drain.
The preservation thesis here is straightforward: NAD+ decline with age is not inevitable in the sense that it is immutable — it is driven by two tractable mechanisms (rising CD38, falling NAMPT) that can be partially addressed. Preserving mitochondrial function, DNA repair capacity, and sirtuin signaling before the organ systems that depend on them begin to fail is the logic. A complementary mitochondrial pathway — mitophagy via Urolithin A — operates independently of NAD+ and has shown immune-aging benefits in a 2025 RCT; the two approaches are additive rather than redundant. This is maintenance before the breaking point, not reversal of established damage. For comparison, the mTOR pathway — which operates in parallel to NAD+/sirtuin signaling — is covered in our deep dive on rapamycin in humans.
What the precursor literature has not yet delivered — and what honest coverage of this space must say plainly — is a human trial showing that NMN or NR supplementation meaningfully delays clinical disease, reduces all-cause mortality, or extends healthspan in a powered study. The mechanistic case is strong. The biomarker signal is real. The hard endpoint confirmation is not there yet. Both things are true simultaneously, and conflating them is how a genuine and interesting area of biology gets buried in marketing noise. The same pattern applies across the longevity field — see our coverage of the first human epigenetic reprogramming trial for another example of how a compelling mechanism reaches early human data.
References
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
- Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717–1728.
- Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.
- Mehmel M, et al. Nicotinamide riboside — the current state of research and therapeutic uses. Nutrients. 2020;12(6):1616.
- Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE. 2012;7(7):e42357.
- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139.
- Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806.
- Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153–160.
- Remie CM, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413–426.
- Grozio A, et al. (Imai lab). Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47–57. [Contested: see Schmidt MS & Brenner C, Nat Metab 2019, who challenge the transporter assignment.]